Who is the lecturer invited for the JPI seminar on April 9th, 2026?

The lecturer is Mr. Yasuhiro Araki, Director of the Clinical Trial Promotion Office, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare.

When is the date and time scheduled for the JPI seminar to be held?

The seminar is scheduled to be held on Thursday, April 09, 2026, from 09:30 to 11:30.

What does the term 'drug loss' mean according to the lecture overview?

It refers to the problem where medicines approved in Europe and the United States are not developed in Japan.

What are the three main aims of the public and private sectors' joint discussions in Japan?

They aim to (1) strengthen Japan's drug discovery capabilities, (2) rapidly deliver the latest medicines to the public, and (3) build a social system where the cycle of investment and innovation is sustained.

AI News NQ Analysis

[JPI Seminar] Ministry of Health, Labour and Welfare "Building a Drug Discovery Ecosystem and Measures to Promote Clinical Trials" to be held on Thursday, April 9th

NQ Score 50/100

AI analysis data is not yet available.

Frequently Asked Questions

Q: Who is the lecturer invited for the JPI seminar on April 9th, 2026?: A: The lecturer is Mr. Yasuhiro Araki, Director of the Clinical Trial Promotion Office, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare.
Q: What is the title of the lecture presented by Mr. Yasuhiro Araki?: A: The title is 'The Deepening "Drug Loss" Problem and Strengthening Japan's Drug Discovery Capabilities Ministry of Health, Labour and Welfare: Building a Drug Discovery Ecosystem and Measures to Promote Clinical Trials ~ Regulatory Harmonization and Concrete Measures for the Rapid Delivery of the Latest Medicines ~'.
Q: When is the date and time scheduled for the JPI seminar to be held?: A: The seminar is scheduled to be held on Thursday, April 09, 2026, from 09:30 to 11:30.
Q: What does the term 'drug loss' mean according to the lecture overview?: A: It refers to the problem where medicines approved in Europe and the United States are not developed in Japan.
Q: What are the three main aims of the public and private sectors' joint discussions in Japan?: A: They aim to (1) strengthen Japan's drug discovery capabilities, (2) rapidly deliver the latest medicines to the public, and (3) build a social system where the cycle of investment and innovation is sustained.